29 Sep - 3 min read

Revised Trading Statement for the year ended 30 June 2021

Revised Trading Statement for the year ended 30 June 2021

 Ascendis Health Limited
 (Registration number 2008/005856/06)
 (Incorporated in the Republic of South Africa)
 Share code: ASC
 ISIN: ZAE000185005
 (“Ascendis Health” or “the Company”)


Shareholders are referred to the trading statement released by the Company on SENS on 20 September 2021 (“First
Trading Statement”) setting out its expected performance for the year ended 30 June 2021 (“current period”) in
relation to that of the corresponding comparative year ended 30 June 2020 (“comparative period”).

Shareholders are advised that the finalisation of certain year end and audit procedures has resulted in the following
    - the restated comparative figures provided in the First Trading Statement for the comparative period have been
      revised, impacting the percentage and quantum of movements disclosed in the First Trading Statement; and
    - the headline earnings per share and normalised headline earnings per share estimates for total operations for
      the current period has been revised.

There are no changes to the current year continuing operations amounts.

Shareholders should refer to the below revised expected financial performance:

                                     Continuing Operations                                Total Operations

 Cents per share              FY2021         FY2020       % increase /      FY2021           FY2020           % increase /
                                            (Restated)   (decrease) in                      (Restated)       (decrease) in
                                                              loss                                                loss
 Basic loss per Share      308.5 – 371.4      316.7*      (3%) - 17%     204.5 - 244.6        202.3*          1% - 21%

 Headline loss per share   300.9 – 346.4      229.4*      31% - 51%      111.4 – 119.1*        38.9*         186% - 206%
 Normalised headline
                           251.9 – 290.4      193.7*      30% - 50%       25.3 – 26.6*         (6.5)*        490%- 510%
 loss/(profit) per share
*Revised from First Trading Statement.

As noted in the First Trading Statement, the restatement of prior year results is driven by, inter alia, the requirements of
IFRS 5: Non-current assets held for sale and discontinued operations, which requires the comparative results for
discontinued operations to be restated. Further revised details on the figures which comprise the restatements of prior
year comparative information will be provided in the detailed results announcement which will be published by the
Company on 30 September 2021.

This trading statement and operational update is the responsibility of the directors and the financial information on which
this statement is based has not been reviewed or reported on by the external auditors.

29 September 2021


Questco Corporate Advisory Proprietary Limited

PM1 - Normalised EBITDA, Normalised headline earnings and normalised headline earnings per share are alternative
performance measures or non-IFRS measures. Further details regarding the computation of the performance
measures and its purpose can be found on the Company’s website via: : https://ascendishealth.com/wp-

Date: 29-09-2021 03:12:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Ascendis Health Limited (JSE:ASC) when you join Listcorp.